Zobrazeno 1 - 10
of 431
pro vyhledávání: '"Kenji, Takeda"'
Autor:
Saki Tanaka, Motohiro Tamiya, Satoshi Nishiuma, Sayaka Nakamura, Keisuke Nozaki, Naoko Watanabe, Chisae Itoh, Yukio Kadokawa, Kenji Takeda, Kozo Takahashi, Akito Miyazaki, Takahisa Kawamura, Kei Kunimasa, Takako Inoue, Kazumi Nishino, Mari Takagi
Publikováno v:
Cancer Treatment and Research Communications, Vol 40, Iss , Pp 100836- (2024)
Background: The most recommended treatment for stage IV EGFR-positive lung cancer is osimertinib monotherapy. The dosage of osimertinib is fixed at 80 mg/day regardless of body surface area (BSA), however some patients withdraw or reduce the dosage d
Externí odkaz:
https://doaj.org/article/4b349845690a4c3a9c26c010b0b54cf5
Publikováno v:
Biomolecules, Vol 14, Iss 2, p 202 (2024)
Advanced glycation end-products (AGEs) have recently been implicated in the onset/progression of lifestyle-related diseases (LSRDs); therefore, the suppression of AGE-induced effects may be used in both the prevention and treatment of these diseases.
Externí odkaz:
https://doaj.org/article/cdbb1a6d0eb540d9b5dc6cc380ae9132
Publikováno v:
Cells, Vol 12, Iss 24, p 2838 (2023)
Advanced glycation end-products (AGEs), formed through glyceraldehyde (GA) as an intermediate in non-enzymatic reactions with intracellular proteins, are cytotoxic and have been implicated in the pathogenesis of various diseases. Despite their signif
Externí odkaz:
https://doaj.org/article/14ba11bbbf7642c68b82c91671b79c6a
Publikováno v:
北海学園大学経営論集. 6(4):55-70
Publikováno v:
北海学園大学経営論集. 6(4):1-54
Publikováno v:
北海学園大学経営論集. 6(4):185-194
Publikováno v:
北海学園大学経営論集. 6(4):125-135
Publikováno v:
北海学園大学経営論集. 6(4):163-184
Publikováno v:
北海学園大学経営論集. 6(4):137-148
Publikováno v:
北海学園大学経営論集. 6(4):71-88